Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to assess the safety of two-week administration of 80 and 160 mcg of ipratropium
bromide as delivered by the RESPIMAT® device and as determined by 24 hours ambulatory ECG
monitoring in COPD patients. To assess the overall safety of the two doses of ipratropium
bromide as delivered by the RESPIMAT® device when administered over a two-week period.